TCRX•benzinga•March 5, 2025 at 12:12 PM

TScan Therapeutics Q4 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate, Sales $665.00K Miss $1.35M Estimate, Cash, Cash Equivalents, And Marketable Securities Of $290.1M To Fund Operations Into Q1 Of 2027

No summary available.

Read the full article from the original source for complete details and context.

Article published on March 5, 2025 by benzinga